Abstract: |
Background: The management of patients with liver and biliary malignancies is rapidly changing. Over the past year, important new studies have been published that offer new treatment options for patients with hepatobiliary cancers. Methods: This article summarizes the top studies published in hepatobiliary cancer over the past year and describes how this latest evidence will impact clinical practice. Results: Advances in systemic therapy with immune checkpoint inhibition and precision oncology approaches for primary liver cancers were reported. For colorectal liver metastases, long-term results from one large randomized trial report limited effects of chemotherapy on overall survival following liver metastasectomy. Conclusions: Key new evidence informs that treatment strategies for hepatobiliary cancer are now available and should be incorporated into practice to improve outcomes for patients with liver and biliary malignancies. © 2023, Society of Surgical Oncology. |